Pliant Therapeutics Current Ratio 2019-2021 | PLRX

Pliant Therapeutics current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Pliant Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.25B $0.01B 22.93
2021-03-31 $0.27B $0.01B 26.39
2020-12-31 $0.29B $0.01B 25.07
2020-09-30 $0.31B $0.01B 27.91
2020-06-30 $0.32B $0.01B 26.95
2020-03-31 $0.18B $0.01B 18.41
2019-12-31 $0.11B $0.01B 13.69
2019-09-30 $0.00B 0.00
2019-06-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-12-31 $0.06B $0.01B 12.14
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.598B $0.042B
Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86